Skip to main content

Galectin Therapeutics Inc 8-K, filed Nov 16, 2026

Galectin Therapeutics Inc (GALT)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Galectin Therapeutics Inc filed this 8-K on November 16, 2026.

Galectin Therapeutics converted debt from five credit facilities, eliminating $105.8 million of debt, and reported $11.7 million of cash. It believes this funds planned operations through June 2027 and filed belapectin’s registrational Phase 3 protocol with FDA in 3Q 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits